Skip to main content
SpringerLink
Log in

Adalimumab/infliximab/vedolizumab

Non-responsiveness: 10 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Sorrentino D, et al. Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 27: 1237-1247, No. 8, Aug 2021. Available from: URL: https://academic.oup.com/ibdjournal/issue

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab/infliximab/vedolizumab. Reactions Weekly 1896, 22 (2022). https://doi.org/10.1007/s40278-022-10813-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-10813-9

Search

Navigation